CAJ | 학술논문

目的：：探讨联合检测血清Cyfra 21-1、CK19-2G2在非小细胞肺癌患者中的诊断。方法：采用化学发光免疫法检测92例非小细胞肺癌患者、83例肺部良性疾病患者和90例健康体检者血清Cyfra 21-1、CK19-2G2的浓度，并判断两者的相关性。比较单独与联合检测Cyfra21-1、CK19-2G2对于诊断非小细胞肺癌的灵敏度和特异性。结果：非小细胞肺癌组血清Cyfra 21-1、CK19-2G2水平显著高于肺部良性疾病组和健康对照组( P<0.01)；非小细胞肺癌患者血清Cyfra 21-1与CK19-2G2水平呈正相关性( P<0.05)。两者联合诊断非小细胞肺癌的灵敏度为82.7％、特异性为78％。结论：Cyfra 21-1、CK19-2G2是有效的诊断非小细胞肺癌的肿瘤标志物。血清Cyfra 21-1、CK19-2G2水平在非小细胞肺癌的诊断中有临床应用价值，两者联合检测的灵敏度和特异性高。
목적：：탐토연합검측혈청Cyfra 21-1、CK19-2G2재비소세포폐암환자중적진단。방법：채용화학발광면역법검측92례비소세포폐암환자、83례폐부량성질병환자화90례건강체검자혈청Cyfra 21-1、CK19-2G2적농도，병판단량자적상관성。비교단독여연합검측Cyfra21-1、CK19-2G2대우진단비소세포폐암적령민도화특이성。결과：비소세포폐암조혈청Cyfra 21-1、CK19-2G2수평현저고우폐부량성질병조화건강대조조( P<0.01)；비소세포폐암환자혈청Cyfra 21-1여CK19-2G2수평정정상관성( P<0.05)。량자연합진단비소세포폐암적령민도위82.7％、특이성위78％。결론：Cyfra 21-1、CK19-2G2시유효적진단비소세포폐암적종류표지물。혈청Cyfra 21-1、CK19-2G2수평재비소세포폐암적진단중유림상응용개치，량자연합검측적령민도화특이성고。
Objective:To investigate the clinical diagnostic value of the combined detection of serum Cyfra 21-1 and CK19-2G2 in patients with the non-small cell lung cancer ( NSCLC ) . Methods:The levels of serum Cyfra 21-1 and CK19-2G2 in 92 cases of NSCLC,83 of benign lung diseases and 90 of healthy controls were detected by chemiluminescent immunoassay. And the correlation between Cyfra 21-1 and CK19-2G2 was evaluated.Moreover,the sensitivity and specificity of combined detection of serum Cyfra 21-1 and CK19-2G2 for of the diagnosis of the NSCLC was compared with detection of either alone.Results:The Cyfra 21-1 and CK19-2G2 levels in serum of the NSCLC patients were significantly higher than those with benign lung disease and healthy controls (P<0.01).The Cyfra 21-1 and CK19-2G2 levels of the NSCLC patients were positively correlated (P<0. 05).Combined detection of both biomarkers in NSCLC yielded a sensitivity of 82.7% and a specificity of 78%. Conclusions:Cyfra 21-1 and CK19-2G2 are effective tumor markers for the diagnosis of NSCLC. With high sensitivity and specificity of the combined detection,serum Cyfra 21-1 and CK19-2G2 levels are clinically useful in the diagnosis of NSCLC.